Stryker Corporation
NYSE:SYKMedical - Devices
+$9.29 today
- Market cap
- $121.12B
- Beta
- 0.79
- P/E (TTM)
- 35.6
- EPS (TTM)
- $8.72
- Dividend yield
- 1.11%
Volume 3.25M
Average 2.49M
SYK Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Stryker CorporationNYSE: SYK
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 42.8% from a year ago
Cash & equivalents stood at $3.39B at the end of Q2 FY2026, up 42.8% from a year earlier and up 17.8% from the prior quarter. Over 3 fiscal years it compounded at +29.6% a year.
Context
- Cash & equivalents amounted to 7.1% of total assets at the end of Q2 FY2026, up 1.9 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +42.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 4.01B USD
- Year-over-year change
- +9.8%
- 4-year CAGR
- +8.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.01B | +9.8% |
| FY2024 | 2024-12-31 | 3.65B | +22.9% |
| FY2023 | 2023-12-31 | 2.97B | +61.1% |
| FY2022 | 2022-12-31 | 1.84B | -37.4% |
| FY2021 | 2021-12-31 | 2.94B | — |
Cash & Equivalents vs competitors
How SYK compares with its peers on the latest reported figures
- SYK's Jun 2026 cash & equivalents of $3.39B is the highest of the 11 companies compared; the peer median is $188.36M.
- Its year-over-year change of +42.8% is the 4th highest of 11, against a peer median of -1.1%.
- Cash & equivalents amounts to 7.1% of total assets for SYK, versus a peer median of 6.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.39B | +42.8% | +29.6% | 7.1% | |
| Jul 2026 | $1.69B | +32.8% | +8.1% | 1.8% | |
| Dec 2025 | $557M | -10.0% | +16.8% | 5.3% | |
| Jun 2026 | $507.75M | +121.3% | +51.8% | 9.3% | |
| Jun 2026 | $410M | -26.4% | +16.4% | 1.8% | |
| Mar 2026 | $236.81M | -1.0% | -19.9% | 6.6% | |
| Mar 2026 | $139.91M | -8.7% | +23.8% | 17.5% | |
| Mar 2026 | $120.28M | +107.5% | +17.4% | 13.6% | |
| Mar 2026 | $35.03M | -1.3% | +12.1% | 1.5% | |
| Apr 2026 | $33.13M | -13.9% | +14.4% | 0.9% | |
| Mar 2026 | $12.16M | +141.6% | -5.6% | 15.6% | |
| Peer median (excluding SYK) | $188.36M | -1.1% | +15.4% | 6.0% | |
Competitors are the stored peer set for SYK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.94B | 1.84B | 2.97B | 3.65B | 4.01B |
| Short-term Investments | 75M | 84M | 82M | 841M | 89M |
| Net Receivables | 3.02B | 3.57B | 3.77B | 3.99B | 4.04B |
| Inventory | 3.31B | 4B | 4.84B | 4.77B | 5.31B |
| Other Current Assets | 662M | 787M | 857M | 1.59B | 1.31B |
| Total Current Assets | 10.02B | 10.28B | 12.52B | 14.85B | 14.76B |
| Property, Plant & Equipment (Net) | 3.25B | 3.44B | 3.71B | 3.96B | 4.4B |
| Goodwill | 12.92B | 14.88B | 15.24B | 15.86B | 19.29B |
| Intangible Assets | 4.84B | 4.89B | 4.59B | 4.4B | 5.68B |
| Long-term Investments | 66M | 90M | 2M | 39M | 2M |
| Tax Assets | 1.76B | 1.41B | 1.67B | 1.74B | 1.1B |
| Other Non-current Assets | 1.78B | 1.9B | 2.18B | 2.13B | 2.62B |
| Total Non-current Assets | 24.61B | 26.61B | 27.39B | 28.12B | 33.09B |
| Total Assets | 34.63B | 36.88B | 39.91B | 42.97B | 47.84B |
| Account Payables | 1.13B | 1.41B | 1.52B | 1.68B | 1.8B |
| Short-term Debt | 119M | 1.31B | 2.24B | 1.55B | 1.15B |
| Tax Payables | 192M | 292M | 391M | 539M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.02B | 2.14B | 2.3B | 2.44B | 2.49B |
| Total Current Liabilities | 4.55B | 6.3B | 7.92B | 7.62B | 7.79B |
| Long-term Debt | 12.47B | 11.86B | 10.9B | 12.19B | 14.86B |
| Deferred Tax Liabilities | 68M | 67M | 63M | 82M | 137M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.36B | 1.68B | 2.08B | 2.07B | 2.29B |
| Total Non-current Liabilities | 15.21B | 13.97B | 13.4B | 14.72B | 17.63B |
| Total Liabilities | 19.75B | 20.27B | 21.32B | 22.34B | 25.42B |
| Common Stock | 38M | 38M | 38M | 38M | 38M |
| Retained Earnings | 13.48B | 14.77B | 16.77B | 18.53B | 20.47B |
| Accumulated OCI | (531M) | (221M) | (416M) | (293M) | (687M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 14.88B | 16.62B | 18.59B | 20.63B | 22.42B |
| Total Debt | 12.9B | 13.53B | 13.49B | 14.12B | 16.36B |
| Net Debt | 9.96B | 11.68B | 10.52B | 10.47B | 12.35B |
Stryker Corporation
NYSE:SYK
Intrinsic Alpha fair value
Locked
Current Price
$318.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.